Abstract. Borna disease was originally described as an equine neurologic syndrome over 200 years ago, although the infectious etiology of the disorder was unproven until the early 20th century. Borna disease virus (BDV) was finally isolated from horses dying of the disorder, and that virus has been used to experimentally reproduce Borna disease in several species of laboratory animals. However, BDV has never been inoculated back into horses to experimentally and etiologically confirm the classic clinical, pathologic, and serologic characteristics of the disease in that species. Three ponies were intracerebrally inoculated with different amounts of BDV and were evaluated clinically, serologically, and neurohistopathologically. All 3 animals developed the clinical signs characteristically described for naturally occurring Borna disease, including ataxia, torticollis, postural unawareness, rhythmic repetitive motor activities, muscle fasciculation, and cutaneous hyperesthesia and hypoesthesia over several body surfaces. Two ponies died after rapid onset of these signs 28-30 days postinoculation. The third animal made a nearly complete clinical recovery. Seroconversion occurred only after the onset of signs and to a marked degree only in the convalescent animal. Virus was recovered postmortem from 2 of the 3 ponies, and a BDV-specific nucleic acid sequence was detectable in all 3 animals using a reverse transcription-polymerase chain reaction procedure. Gross neural lesions were absent, but histopathologically there was generalized intense mononuclear perivascular cuffing, glial nodule formation, and astrocytosis in all 3 brains. Confirming a diagnosis of Borna disease is difficult and perhaps best accomplished using a combination of the clinical, serologic, and histopathologic indicators of this unusual disease supported by positive reverse transcription-polymerase chain reaction findings.
Borna disease (BD) was originally described as a sporadic, usually fatal neurologic affliction of horses and sheep in southern Germany. 16 The viral etiology of the disease was eventually proven, and the etiologic agent, Borna disease virus (BDV), was propagated in cell cultures. 16 In recent years, however, natural or experimental infections with BDV have been confirmed or suspected in a much wider range of host species, including cattle, cats, ostriches, rodents, rabbits, and possibly humans. 2, 4, 8, [13] [14] [15] In vitro understanding of BDV has also increased dramatically in the last decade as cell culture and molecular techniques have been used to study the virus. [5] [6] [7] 14 BDV is an 8.9-kilobase negative polarity, nonsegmented, enveloped RNA virus that encodes 5 open reading frames (ORF). 7 At least 3 of these ORFs are expressed in infected animals and cell cultures, and animals may respond serologically to these 3 expressed proteins: p14, p24, and p38-40. 3, 14 There are no published reports of experimental BDV infections in horses, which have historically been considered the prototypic natural virus host. The study reported here was designed to provide an experimentally confirmed diagnostic clinical, serologic, and routine histopathologic profile of BDV infection in horses.
Materials and methods
Animal procedures. Three young adult ponies (2 mares and 1 gelding, 225 kg each) were selected for this study based upon their BDV seronegative status as determined both by indirect immunofluorescence using fixed BDV-infected cells and by p14, p24, and p38-p40 native BDV antigen immunoblots of preinoculation sera. The animals were selected from a randomly assembled group of 12 ponies, about half of which had sera reactive with 1 of the BDV immunoblot antigens, usually p24. The selected animals were housed individually in biosafety level 3 (BL3) facilities and monitored clinically for 4 wk prior to virus inoculation. Rectal temperatures were taken daily. At the time of BDV inoculation, horses were anesthetized and prepared for surgery. A sterile 0.16-cm-diameter drill was used to penetrate the parietal calvarium 2.54 cm parasaggital and 5.1 cm retroorbital. A 1.0-ml suspension of CRP 3 strain BDV (provided by one of us [KMC]) was then instilled through a 25-gauge, 8.9-cm spinal needle into each animal's brain. Ponies 26, 31, and 368 thus received, respectively, 2 ϫ 10 4 TCID 50 , 5 ϫ 10 3 TCID 50 , and 1 ϫ 10 3 TCID 50 of BDV intracerebrally. Animals recovered uneventfully. Clinical monitoring contin-ued 1 or more times daily during the ensuing weeks. Animals were eventually euthanized when clinical signs of BD became severe (ponies 26, 31) or after the attainment of a clinically stable BD convalescent status (pony 368). At necropsy, 1 brain hemisection, sections of thoracic and cervical spinal cord, sciatic nerve, nasolabial skin, eye, lung, liver, kidney, spleen, and mesenteric lymph nodes were fixed in 10% (v/v) neutral buffered formalin for subsequent hematoxylin and eosin staining followed by histopathologic examination. Additional samples of these tissues, as well as blood and urine specimens, were frozen (Ϫ70 C) for later virus isolation attempts. For serologic analysis, blood samples were taken from each pony twice during a 4-wk period prior to BL3 confinement and virus inoculation and at weekly intervals thereafter until euthanasia.
Serologic analyses. Anti-BDV antibody titers were determined by indirect immunofluorescence (IFA) and by immunoblot assays as previously described. 18 For IFA, pony sera were diluted serially in 2% (v/v) normal goat serum in 0.01 M phosphate-buffered saline and then incubated on acetone-fixed monolayers of uninfected and persistently BDVinfected rat astrocytoma C6 cells. a,b Cells were incubated with fluorescein isothiocyanate-conjugated goat anti-equine IgG antibody. b The end point titer was the reciprocal of the greatest serum dilution producing specific fluorescence. For immunoblot, native BDV antigens were prepared from a BDV-infected neuroblastoma cell culture lysate as previously described. 18 Lysate was loaded onto 15% (w/v) polyacrylamide gels, and the separated p14, p24, and p38-40 antigens were then blotted to nitrocellulose following electrophoresis. After 16-hr incubations with 1:200 (v/v) dilutions of horse sera, blots were incubated with peroxidase-conjugated goat anti-equine IgG antibody. c Specifically bound labeled indicator antibodies were then visualized using an enhanced chemiluminescence substrate system. d Pre-and postinoculation sera were also tested using a competitive enzyme-linked immunoassay (cELISA). The cELISA utilized baculovirus-expressed p38-40 recombinant BDV antigen along with an anti-(p38-40) monoclonal antibody. 9 The reagents, e,f format, and protocol of this cELISA were in all other respects identical to 2 other recently described baculovirus antigen-monoclonal antibody-based cELISAs. 11, 12 Sera were evaluated to their end points using this BDV cELISA; the end point was defined as the greatest serum dilution producing Ն40% inhibition of the optical density (OD 405 ) relative to each pony's preinoculation serum cELISA OD 405 . The IFA and immunoblot procedures were applied to selected postinoculation sera to confirm the validity of the cELISA findings.
Virus isolation, bioassay, and viral nucleic acid detection. For each pony, weighed samples of saggitally sectioned and midcoronally sectioned whole brain were homogenized and sonicated in 5-fold volumes (1:5 w/v) of cell culture medium and then serially diluted in 10-fold increments. Following low-speed centrifugal clarification, these dilutions were inoculated onto monolayers of C6 cells. Attempts to demonstrate infectivity were then made 7-10 days later using the indirect immunofluorescence assay on these monolayers as described. Homogenate from each of the 3 brains was also inoculated intracranially (0.05 ml) into 2 young adult Lewis rats. These 6 rats were observed for neurologic deficits and euthanized 60-65 days post-inoculation, and their brains were tested for the presence of BDV using the same cell culture procedure. 4 Reverse transcription-polymerase chain reaction (RT-PCR) assays were also performed on neural tissue homogenates from each pony using methods previously described. 17 Positive RT-PCR results were confirmed using a previously developed hybridization procedure directed against an internal portion of the amplified PCR product. 17 Infected and uninfected C6 cell culture controls were concurrently tested to ensure the integrity of both the virus isolation and RT-PCR procedures.
Results

Clinical findings
All 3 ponies remained clinically normal for Ͼ2 weeks following virus inoculation. The onset of signs began in a dose-related manner, with the animal receiving the greatest infectious inoculum succumbing first (Table 1) . A brief, abrupt pyrexia occurred in 2 of the 3 ponies (nos. 26, 31), terminating immediately prior to the onset of neurologic signs ( Table 1 ). The ensuing period of neurologic dysfunction ranged from 3 to 16 days depending on the animal involved. Although each animal manifested some unique signs, all animals became ataxic, circled, assumed unusual postures, tilted the head and neck, exhibited generalized muscle fasciculations, and demonstrated cutaneous hyperesthesia and hypoesthesia over various skin surfaces (Table 1 ). All animals also developed an apparent environmental unawareness and engaged in repetitive motor activities such as head bobbing and lip smacking. Ponies 26 and 31 were euthanized when they became recumbent and moribund within 72 hours after the onset of signs. Pony 368, which received the smallest viral inoculum, stabilized and then rapidly returned to a near normal neurologic state for about 2 weeks. After that period, the animal became gradually aggressive and hyperactive and was then euthanized.
Pathologic findings
Gross postmortem lesions were not seen. Histologic lesions were confined to the central nervous system. Lesions in the 2 most acutely affected ponies (nos. 26, 31) were similar, with prominent mononuclear perivascular cuffing in the gray matter throughout the entire brain. These perivascular cuffs varied in thickness; many were 8-10 cells in depth. Mesencephalon, thalamus, and hippocampus were most severely involved. Moderate astrocytosis, neuronophagic nodules, mild axonal swelling and degeneration, and focal glial nodules were observed in the upper brain stem and cerebral regions of both brains. The brain of the chronically affected pony (no. 368) had perivascular cuffs in the same regions, but cuffs were extremely thick (up to 20 cell layers in many areas) and contained many macrophages. Perivascular cuffing was most pronounced around arterioles. Milder perivascular cuffing was also seen in the gray matter of the cervical and thoracic spinal cord but not in the lumbar region. Multifocal moderate gliosis was distributed throughout the gray matter from cervical spinal cord through cerebrum.
Serology
Ponies were selected for study based upon repeated IFA, cELISA, and immunoblot BDV-seronegative status. At death, pony 31 was cELISA seronegative and weakly seropositive by IFA and reacted serologically only with the p14 and p24 antigens by immunoblot. Pony 26, which died after a brief illness marked by intense neurologic dysfunction, was only marginally seropositive by IFA and cELISA and seroreacted with only the p14 and p24 antigens by immunoblot. Pony 368 survived and seroconverted at about the same time postinoculation as did the other 2 ponies (Table 1) . However, pony 368 developed steadily rising titers during convalescence; the IFA reached a 1:12,000 end point, the cELISA reached a 1:5,120 end point, and sera reacted strongly by immunoblot with p38-40 and the p14 and p24 viral antigens (Figs. 1-3 ).
Virus isolation, bioassay, and viral nucleic acid detection
Repeated attempts to demonstrate viral infectivity by direct cell culture bioassay of each pony's brain homogenate were negative for each animal. By RT-PCR, however, BDV-specific viral nucleic acids were demonstrated in brain samples from all 3 animals. Furthermore, infectious virus was recovered from the brains of 2 of the 6 bioassay rats, 1 that received pony 26 brain homogenate and 1 that received pony 368 brain homogenate. Positive and negative control specimens tested concurrently by each technique gave expected results, indicating proper performance of these procedures.
Discussion
This is the first report of experimental intracranial inoculation of ponies with BDV even though the disease was first described in and is usually associated with horses and sheep. 16 As in experimentally infected Immunoblot of pony sera against BDV uninfected and persistently infected human neuroblastoma cell culture lysates. Lanes 1, 3, and 5 contain uninfected cell lysate antigens. Lanes 2, 4, 6, and 7 contain lysate of persistently infected cell cultures. Serum from pony 368 (34 DPI) was incubated in lanes 1 and 2, serum from pony 26 (30 DPI) was incubated in lanes 3 and 4, serum from an uninoculated control pony was incubated in lanes 5 and 6, and hyperimmune rabbit anti-BDV sera was incubated in lane 7. Numbers indicate approximate molecular mass (kilodaltons) of the 3 major BDV antigens expressed in the infected cell cultures. Serum from pony 368 reacted with all 3 antigens, whereas serum from pony 26 reacted with only the p14 and p24 antigens. rats, 4 the period of preclinical incubation was inversely proportional to the viral dose administered. Despite the iatrogenic mode of virus transmission used in this study, clinical signs were strikingly similar to classic descriptions of acute BD in naturally infected horses. 16 The natural mode of BD transmission cannot be inferred from this study. However, other species have been experimentally infected by the respiratory route, and that route has been suggested as the method of transmission in nature. 4 It would be interesting to repeat this study using that route of inoculation. Although BD has never been diagnosed in the United States, diagnosticians should consider this malady in horses exhibiting depression, ataxia, unnatural postures, fasciculations, circling, head tilt and torticollis, repetitive motor activities, and seeming environmental unawareness. Hyperthermia may not be observed because it may be brief and may precede the onset of neurologic signs. Hyperthermia and length of the preclinical interval appeared to be dose related in this study. Borna disease is usually considered an acutely fatal illness in horses. 16 These findings suggest that horses infected with small amounts of BDV may survive long enough to develop chronic behavioral abnormalities. The surviving pony in this experiment did become restless and aggressive after recovering from the brief interval of acute neurologic dysfunction. The brain of this animal was virus positive at the time of euthanasia, as shown by rat bioassay. This finding suggests that convalescent animals may harbor infectious BDV and may serve as reservoirs for subsequent virus transmission to other animals.
The consistent and salient, but not pathognomonic, histopathologic findings observed in these 3 cases of BDV infection were marked perivascular cuffing throughout the gray matter of the brain, particularly in the midbrain, along with widely scattered focal gliosis, neuronophagia, and mild to moderate axonal swelling and degeneration. The Joest-Degen inclusion bodies historically noted in BD neuropathology were not observed in these ponies. Such inclusions in animals dying of acute BD could be confused with Negri bodies seen in animals with rabies.
Histopathologically, other differential diagnoses might include the eastern, western, and Venezuelan equine encephalitides (EEE, WEE, VEE). Rabies and EEE and VEE would not be likely diagnoses in convalescent horses surviving acute BD because of the invariably or usually fatal acute course of the former infections.
The results of this study indicate that BDV serologic and virus isolation tests in horses must be interpreted cautiously for several reasons. None of the 3 ponies had strongly seroconverted by IFA or cELISA at the time neurologic signs appeared, and 2 of the animals were seronegative or only marginally seropositive at the time of death, depending on the animal and the serologic test involved. Viral infectivity was not directly recovered postmortem but required intermediate rat bioassay followed by cell culture isolation. These findings support the classical observations that horses dying acutely of BD may frequently be seronegative and virus isolation negative, hence serology and virus isolation may be of limited help in these instances. 14, 16 Conversely, the surviving pony developed high convalescent anti-BDV titers by all 3 serologic measures employed, but the clinical signs were reduced by the time this occurred. Seroconversion did not occur simultaneously on the IFA, cELISA, and immunoblot tests as animals initially became seropositive to BDV. In this study and in other studies of experimental BDV infections in other species, 3, 8, 14 animals did not necessarily seroconvert (as determined by immunoblot) to all 3 major BDV antigens (p14, p24, p38-40) at the same time. These factors may underlie some of the difficulties in interpreting discordant BDV serologic test results. 3, 8, 10, 13, 14 Because BDV isolation is notoriously difficult, well-controlled RT-PCR procedures may be useful in detecting the presence of BDV nucleic acid in postmortem brain samples, as was true in this study.
Immunoblots are often considered a definitive means of resolving serologic uncertainties. Twelve apparently healthy yearling ponies were tested by immunoblot for BDV antibodies prior to selecting the 3 animals used in this study. Four of those not selected had sera reactive with the BDV p24 antigen band. These ponies had no clinical or historical evidence of BDV infection. Perhaps antigenic mimicry is responsible for this perplexing finding; if so, this mimicry would further complicate serodiagnostic interpretations. This observation is pertinent because several recent studies have reported serologic evidence of BDV exposure in animal and human populations not previously known to harbor BDV. 1, 10, 13 Possible antigenic mimicry, absence of antibody in clinically ill animals, appearance of different antigen-specific antibodies at different times postinfection, and the presence of antibodies in clinically normal convalescent animals all complicate seroepidemiologic studies of BDV exposure in animal populations. In response to these concerns, some investigators have used stringent criteria for diagnosing seropositivity, requiring the recognition of Ն2 BDV proteins by immunoblot or immunoprecipitation prior to a seropositive classification. 17 Isolation of BDV, although difficult, is probably the surest means of verifying the existence of BDV in populations in which it has not been previously encountered. Routine pathologic findings will likely be limited to essentially nonspecific central nervous system histopathologic changes of other chronic neuroinflammatory diseases such as EEE, WEE, and VEE. Lacking positive virus isolation findings, perhaps multiple antigenic recognition (p14, p24, p38-40) by serum on immunoblot, rising anti-BDV serologic titers, and recognition of multiple BDV antigens in brain tissue by monoclonal antibody immunohistochemical examination would be other reliable approaches for diagnosing BDV exposure in horses.
